Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

29.13
-0.3550-1.20%
Volume:398.30K
Turnover:11.57M
Market Cap:6.01B
PE:-10.34
High:29.64
Open:29.37
Low:28.79
Close:29.48
52wk High:45.42
52wk Low:16.77
Shares:206.40M
Float Shares:89.57M
Volume Ratio:0.70
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8178
EPS(LYR):-2.7716
ROE:-80.10%
ROA:-46.73%
PB:8.17
PE(LYR):-10.51

Loading ...

How Investors May Respond To Immunovant (IMVT) After Sjögren’s Trial Failure

Simply Wall St.
·
Oct 10

Immunovant down after Argenx study fails in Sjogren’s disease

TIPRANKS
·
Oct 08

Immunovant CEO Eric Venker Disposes of Common Shares Worth $2.93 Million

Reuters
·
Oct 06

Roivant President and Immunovant CEO Eric Venker Disposes of 200,000 Common Shares Worth $7,324,000

Reuters
·
Oct 03

Is Trial Failure Altering The Investment Case For Immunovant Stock (IMVT)?

Simply Wall St.
·
Oct 02

Immunovant (IMVT) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 26

Bernstein Reaffirms Their Hold Rating on Immunovant (IMVT)

TIPRANKS
·
Sep 26

Immunovant Down over 7%, on Pace for Largest Percent Decrease Since July 2025

Dow Jones
·
Sep 24

Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program

Dow Jones
·
Sep 24

Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)

TIPRANKS
·
Sep 24

Immunovant Proof-of-Trial for IMCT-1402 Misses Primary Endpoint

Dow Jones
·
Sep 23

Sector Update: Healthcare

MT Newswires Live
·
Sep 23

Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks

MT Newswires Live
·
Sep 23

Immunovant Falls After Lupus Drug Setback

Reuters
·
Sep 23

Roivant announces trial of IMVT-1402 did not reach statistical significance

TIPRANKS
·
Sep 23

Immunovant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus

THOMSON REUTERS
·
Sep 23

Immunovant, - Imvt-1402 Study in Cle Did not Achieve Statistical Significance on Primary Endpoint

THOMSON REUTERS
·
Sep 23

Immunovant, - to Stop Development of Imvt-1402 in Cle

THOMSON REUTERS
·
Sep 23

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

GlobeNewswire
·
Sep 23

Analysts’ Top Healthcare Picks: LeonaBio (LONA), Immunovant (IMVT)

TIPRANKS
·
Sep 21